Aim To explore the clinical effects of high dose rosuvastatain on inflammatory factors of angina patients treated with percutaneous coronary intervention（PCI）. Methods The study was carried out with 150 angina patients receiving PCI during February 2013 to October 2014. The patients were divided into five groups by preoperative rosuvastatain dose, namely low dose group（LD, 5 mg/d）, moderate-low dose group（MLD, 10 mg/d）, moderate dose group（MD, 15 mg/d）, moderate-high dose group（MHD, 20 mg/d）, and high dose group（HD, 25 mg/d）. Each group consisted of 30 patients. All patients were treated with 5 mg/d rosuvastatain after PCI. The preoperative and postoperative （24 h） interleukin 6（IL-6）, interleukin 10（IL-10）, interferon γ（IFN-γ）, and tumor necrosis factor α（TNF-α） were tested. Results The IL-6, IFN-γ and TNF-α levels in group LD were significantly higher during postoperative period than preoperative period（P<0.05） IL-6 and IFN-γ levels in group MLD were significantly greater during postoperative period than preoperative period（P<0.05） IL-6, IFN-γ and TNF-α levels in group MD, MHD, and HD during postoperative period had no significant difference compared with that in preoperative period（P>0.05）, but IL-10 level was significantly greater during postoperative period than preoperative period（P<0.05）. The 15 mg/d rosuvastatain dose could effectively reduce inflammatory factor levels and increase anti-inflammatory factor levels, and further increases in the rosuvastatain dose had no significant influences on inflammatory factor levels. Conclusions Relatively higher dose of rosuvastatain （15 mg/d） during preoperative period could reduce inflammatory factor levels and increase anti-inflammatory factor levels.